NIH Granted Gene Therapy Patent

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

WASHINGTON--The U.S. Patent and Trademark Office has awarded a broad patent on gene therapy to the National Institutes of Health. Six years after filing the application, NIH and its licensee, Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use the patent for ex vivo human gene therapy.

WASHINGTON--The U.S. Patent and Trademark Office has awarded abroad patent on gene therapy to the National Institutes of Health.Six years after filing the application, NIH and its licensee,Genetic Therapy, Inc. of Gaithersburg, Maryland, can now use thepatent for ex vivo human gene therapy.

In this technique, human cells are manipulated in the laboratoryto express potentially therapeutic genes, which are then introducedinto a patient to treat disease. Coinventors of the techniqueare Michael Blaese, MD, and Stephen A. Rosenberg, MD, PhD, bothNIH scientists, and W. French Anderson, MD, a former NIH researchernow at the University of Southern California Norris Cancer Center.

Recent Videos
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
9 Experts are featured in this series.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
9 Experts are featured in this series.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.